Tag Archives: CYTR

buy stock market

FBI Director James Comey

According to top Senate Democrat Harry Reid (D-NV), the FBI is withholding an “October Surprise” that would harm GOP presidential candidate Donald Trump’s campaign ahead of Election Day on Nov. 8…

The outspoken Democrat issued a scathing public letter via his own website to FBI Director James Comey yesterday (Sunday).

He criticized Comey’s disclosure last Friday (Oct. 28) that the FBI is reopening its investigation into Hillary Clinton’s emails based on new evidence the agency recently obtained.

Don’t Miss:This YUGE 325% profit opportunity from our Chief Investment Strategist Keith Fitz-Gerald –which is only available until tomorrow…

Reid’s scathing memo accused Comey of “partisan actions” and even suggested he “may have broken the law.” This latter statement is in reference to the Hatch Act of 1939, which bars the use of an executive branch position to influence an election.

buy stock market: Atlantic Power Corporation(AT)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Monday, utilities shares rose by just 0.1 percent. Meanwhile, top losers in the sector included Atlantic Power Corp (NYSE: AT), down 2 percent, and Pampa Energia S.A. (ADR) (NYSE: PAM), down 4 percent.

  • [By Lisa Levin] Related WR Earnings Scheduled For February 24, 2016 Mid-Day Market Update: Ocata Therapeutics Climbs On Acquisition News; Textura Shares Slip Related AT Mid-Morning Market Update: Markets Open Higher; Tiffany Misses Q2 Expectations PVH Corp, Atlantic Power, Carlyle Group Lead Monday's After-Hours Movers Atlantic Power's (AT) CEO Jim Moore on Q4 2015 Results – Earnings Call Transcript (Seeking Alpha)

    Toward the end of trading Thursday, the Dow traded down 0.24 percent to 16,960.40 while the NASDAQ declined 0.38 percent to 4,656.49. The S&P also fell, dropping 0.17 percent to 1,985.91.

buy stock market: Retail Properties of America, Inc.(RPAI)

Advisors’ Opinion:

  • [By Ant贸nio Costa]

    Retail Properties of America Inc (NYSE: RPAI) has been in an impressive rebound since the lows of August and the stock price action continues to become Bullish. However, RPAI has run into the downtrend line resistance again and this could lead to a brief period of sideways consolidation or price correction from current levels. On watch.

buy stock market: CytRx Corporation(CYTR)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Another under-$10 biotechnology player that’s starting to trend within range of triggering a major breakout trade is CytRx (CYTR), which has an oncology pipeline that includes two programs in clinical development for cancer indications: aldoxorubicin and tamibarotene. This stock has been moving to the upside during the last three months, with shares up by 21%.

    If you take a look at the chart for CytRx, you’ll notice that this stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $2.27 on the downside and $2.68 on the upside. That consolidation pattern has occurred right above this stock’s 50-day and 200-day moving averages. Shares of CYTR have now started to break out above some near-term overhead resistance at $2.49 a share. That move is quickly pushing CYTR within range of triggering an even bigger breakout trade above the upper-end of its recent sideways trading chart pattern.

    Market players should now look for long-biased trades in CYTR if it manages to break out above some near-term overhead resistance levels at $2.68 to $2.80 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 154,838 shares. If that breakout triggers soon, then CYTR will set up to re-test or possibly take out its next major overhead resistance levels at $3.20 to $4 a share.

    Traders can look to buy CYTR off any weakness to anticipate that breakout and simply use a stop that sits right below its 200-day at $2.33 a share or below more support at $2.27 a share. One can also buy CYTR off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

buy stock market: Monro Muffler Brake, Inc.(MNRO)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Yesterday, shares of Monro Muffler Brake (MNRO) plunged 3.1% after Barron’s Leslie Norton panned the stock in this weekend’s issue of the magazine. And wouldn’t you know it? Monro’s shares are skidding lower once again today.

    Mike Mozart/JeepersMedia

    Norton’s argument was straightforward:

    At a recent $62, Rochester, N.Y.based Monro (ticker: MNRO) trades at a lofty 28 times forward earnings, compared with a 10-year average of 21.1, and 17 times earnings for the Standard & Poors 500. With sales growth slowing as competition increases, Monros strategic goal of achieving 15% annual sales gains and 20% profit growth seems distant.

    Any hint of more sluggish sales could push the shares down at least 10%. Bruce Geller, CEO of money manager Dalton Greiner Hartman Maher, who is short the stock, says, A fairly commoditized business with low organic growth deserves a more reasonable multiple of 20 times.

    That would put the stock in the mid-$40s.

    Shares of Monro Muffler Brake have dropped 4% to $57.59 at 3:49 p.m. today, leaving around 20% of downside.

    UPDATE: This post initially misspelled ‘Brake’ as ‘Break.’ It’s been corrected.

buy stock market: Fox Factory Holding Corp.(FOXF)

Advisors’ Opinion:

  • [By Javier Hasse]

    Fox Factory Holding Corp (NASDAQ: FOXF) was down 1.8 percent after posting a 2.16 percent rise over the day.

    Finally, Groupon Inc (NASDAQ: GRPN) gained 1.3 percent, continuing with the 3.85 percent spike it experienced on Friday trading.

buy stock market: Square, Inc.(SQ)

Advisors’ Opinion:

  • [By Lisa Levin]

    Square Inc (NYSE: SQ) shares dropped 19 percent to $10.58. Square reported a loss of $(0.29) per share and sales of $379 million. Wedbush downgraded Square from Neutral to Underperform.

4 Under-$10 Biotech Stocks in Breakout Territory

DELAFIELD, Wis. (Stockpickr) — At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers.

Read More: Warren Buffett’s Top 10 Dividend Stocks

Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility. Stocks that are making big-percentage moves either up or down are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend — a trend that can lead to huge profits. If you time your trade correctly, combining technical indicators with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let’s take a closer look at a several stocks under $10 that are making large moves to the upside.

Read More: 5 Stocks Set to Soar on Bullish Earnings

OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals (OGXI), a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. This stock closed up 4% to $3.38 in Tuesday’s trading session.

Tuesday’s Range: $3.25-$3.39

52-Week Range: $2.86-$14.25

Tuesday’s Volume: 268,000

Three-Month Average Volume: 211,778

From a technical perspective, OGXI ripped higher here right off its 50-day moving average of $3.29 with above-average volume. This move is quickly pushing shares of OGXI within range of triggering a near-term breakout trade. That trade will hit if OGXI manages to take out some key near-term overhead resistance at $3.45 with high volume.

Traders should now look for long-biased trades in OGXI as long as it’s trending above some near-term support around $3 and then once it sustains a move or close above $3.45 with volume that hits near or above 211,778 shares. If that breakout kicks off soon, then OGXI will set up to re-test or possibly take out its next major overhead resistance levels $3.84 to $4.33. Any high-volume move above those levels will then give OGXI a chance to make a run at $5.

Concert Pharmaceuticals

Concert Pharmaceuticals (CNCE), a clinical stage biopharmaceutical company, discovers and develops small molecule drugs for central nervous system disorders, renal disease, inflammation and cancer. This stock closed up 5.6% to $9.29 in Tuesday’s trading session.

Tuesday’s Range: $8.80-$9.40

52-Week Range: $7.12-$16.26

Tuesday’s Volume: 136,000

Three-Month Average Volume: 156,897

From a technical perspective, CNCE ripped sharply higher here right above some near-term support at $8.67 and back above its 50-day moving average of $8.92 with lighter-than-average volume. This strong move to the upside on Tuesday is starting to push shares of CNCE within range of triggering a near-term breakout trade. That trade will hit if CNCE manages to take out Tuesday’s intraday high of $9.40 to some more near-term overhead resistance at $9.95 with high volume.

Traders should now look for long-biased trades in CNCE as long as it’s trending above some key near-term support at $8.67 and then once it sustains a move or close above those breakout levels with volume that hits near or above 156,897 shares. If that breakout gets underway soon, then CNCE will set up to re-test or possibly take out its next major overhead resistance levels at $10.44 to $10.87. Any high-volume move above those levels will then give CNCE a chance to tag $12 to $13.

AcelRx Pharmaceuticals

AcelRx Pharmaceuticals (ACRX), a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. This stock closed up 4.3% to $6.99 in Tuesday’s trading session.

Tuesday’s Range: $6.64-$7.01

52-Week Range: $6.04-$13.64

Tuesday’s Volume: 723,000

Three-Month Average Volume: 1.13 million

From a technical perspective, ACRX ripped notably higher here right above some near-term support at $6.50 with lighter-than-average volume. This stock recently formed a double bottom chart pattern at $6.11 to $6.06. Following that bottom, shares of ACRX have started to trend higher and it’s now quickly approaching a major breakout trade. That trade will hit if ACRX manages to take out some key near-term overhead resistance levels at $7.15 to its gap-down-day high from July at $7.33 with high volume.

Traders should now look for long-biased trades in ACRX as long as it’s trending above some near-term support at $6.50 or above those double bottom support levels and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.13 million shares. If that breakout gets underway soon, then ACRX will set up to re-fill some of its recent gap-down-day zone that started at $11.38.

CytRx

CytRx (CYTR) operates as a biopharmaceutical research and development company specializing in oncology. This stock closed up 3.7% to $3.29 in Tuesday’s trading session.

Tuesday’s Range: $3.17-$3.36

52-Week Range: $2.00-$8.35

Tuesday’s Volume: 973,000

Three-Month Average Volume: 1.41 million

From a technical perspective, CYTR jumped higher here right above some near-term support at $3.05 with decent upside volume flows. This stock recently formed a double bottom chart pattern at $3.08 to $3.05. Following that bottom, shares of CYTR have started to spike higher and move within range of triggering a big breakout trade. That trade will hit if CYTR manages to take out some near-term overhead resistance levels at $3.42 to its 50-day at $3.66 and then above $3.74 with high volume.

Traders should now look for long-biased trades in CYTR as long as it’s trending above those double bottom support levels and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.41 million shares. If that breakout develops soon, then CYTR will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $4.30 to $4.50.

To see more stocks that are making notable moves higher, check out the Stocks Under $10 Moving Higher portfolio on Stockpickr.

— Written by Roberto Pedone in Delafield, Wis.

RELATED LINKS:

>>3 Stocks Spiking on Unusual Volume

>>5 Hated Earnings Stocks You Should Love

>>These 5 Toxic Stocks Could Be Poisoning Your Portfolio

Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Delafield, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including

CNBC.com and Forbes.com.

You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.

Put CytRx and Ignyta on Your Watchlist. Here’s Why. (RXDX, CYTR)

Quick – what do CytRx Corporation (NASDAQ:CYTR) and Ignyta Inc. (NASDAQ:RXDX) have in common? Yes, they’re both biotech stocks, but that’s not the absolute best answer right now. The most meaningful common element between RXDX and CYTR right now is, each is on the verge of a big technical breakout and deserves a spot on your watchlist. Here’s a closer look at each. 

With a market cap of only $132 million and no revenue, Ignyta Inc. isn’t exactly in a position to turn a lot of heads. On the other hand, biotech trading veterans know all too well that the mere promise and premise of a drug can spur trade-worthy moves from a biotech stock, and RXDX is one of those stocks.

Simply put, Ignyta is working on a drug called entrectinib, in phase 1 trials as a treatment for cancer. It’s a unique approach, in that it combines the use of a diagnostic with a therapy drug that allows something of a customized treatment.

That’s not the interesting part about RXDX right now, however. Indeed, a meaningful milestone for the drug is still years away. What puts Ignyta Inc. on the verge of a breakout move right now is how it’s pushing its way out of a downtrend and into an uptrend. The hurdle of the horizontal resistance line was a big first step, but a move above the $7.09 ceiling could be quite catalytic.

CytRx Corporation is a biopharmaceutical developer best known for an oncology drug known as Aldoxorubicin. It’s being tested as a therapy for a variety of cancers, but is farthest along as a treatment for soft tissue sarcoma (phase 3 as a 2nd line treatment, and phase 2 as a 1st line treatment). CYTR has been dealing with a bout of “can’t win for losing” for a long time, though, with the latest chapter in the saga coming a month ago when the FDA asked the company to suspend trials on the drug due to a patient’s death. Though the cause of death hasn’t been determined, the concern is (obviously) the usage of Aldoxorubicin may have been a contributing factor.

Nothing last forever, though, CytRx shares look like they’ve already fallen as far as they can, and are now testing the waters of higher highs.

The weekly chart of CYTR tells part of the story. Each new low since the early-2014 peak has been less destructive than the prior one, and now, shares are again testing the 100-day moving average line (gray) as resistance.

Zooming into the daily chart of CytRx Corporation we can not only see the pressure almost being put on the 100-day average line, but can see that CYTR is putting pressure on the 50-day moving average line as a ceiling.

A move above the 100-day line at $2.79 could really unleash a lot of pent-up buying.

Want more free stock trading ideas sent to your smartphone or e-mailed to you? Try our new – and free – stock alerts service. Just go here to learn more.